Dallas, TX
United States
University of Texas at Dallas - Division of Digestive and Liver Diseases
patient satisfaction, quality of care, correspondence, health care marketing, patient choice
Advanced HCC, systemic treatment, first line, atezolizumab, bevacizumab
liver cancer; cancer risk prediction; cirrhosis; serum biomarker
hepatocellular carcinoma, surveillance, the United States, Japan, tumor burden, liver dysfunction, prognosis